Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
Trial record 1 of 1 for:    ARD12130
Previous Study | Return to List | Next Study

A Study of Investigational SAR245409 in Patients With Certain Lymphoma or Leukemia

This study has been completed.
Information provided by (Responsible Party):
Sanofi Identifier:
First received: July 26, 2011
Last updated: February 17, 2016
Last verified: February 2016

Primary Objective:

- To evaluate the efficacy of SAR245409 as determined by the objective response rate (ORR) in patients with 1 of following relapsed or refractory lymphoma or leukemia subtypes: mantle cell lymphoma (MCL), follicular lymphoma (FL), chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), or diffuse large B cell lymphoma (DLBCL)

Secondary Objectives:

  • To assess duration of response, progression free survival (PFS), and proportion of patients with PFS at 6 months (24 weeks) in patients with either MCL, FL, CLL/SLL or DLBCL treated with SAR245409
  • To evaluate the safety and tolerability of SAR245409 in patients with MCL, FL, CLL/SLL or DLBCL
  • To further characterize the plasma pharmacokinetics (PK) of SAR245409 in patients with MCL, FL, CLL/SLL or DLBCL

Condition Intervention Phase
Drug: SAR245409
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase 2 Study of SAR245409 in Patients With Relapsed or Refractory Mantle Cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Diffuse Large B Cell Lymphoma

Resource links provided by NLM:

Further study details as provided by Sanofi:

Primary Outcome Measures:
  • Objective response rate (ORR) as defined as the proportion of patients who experience complete response/remission (CR) or partial response/remission (PR) [ Time Frame: 2 months to 2 years ]

Secondary Outcome Measures:
  • Progression free survival (PFS) at 6 months [ Time Frame: 6 months to 2 years ]

Enrollment: 167
Study Start Date: October 2011
Study Completion Date: September 2014
Primary Completion Date: September 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: mantle cell
50 mg twice daily: no eating for 2 hours prior and 1 hour after dose
Drug: SAR245409
Pharmaceutical form:capsule Route of administration: oral
Experimental: follicular lymphoma
50 mg twice daily: no eating for 2 hours prior and 1 hour after dose
Drug: SAR245409
Pharmaceutical form:capsule Route of administration: oral
Experimental: CLL/SLL
50 mg twice daily:no eating for 2 hours prior and 1 hour after dose
Drug: SAR245409
Pharmaceutical form:capsule Route of administration: oral
Experimental: Diffuse large B cell lymphoma
50 mg twice daily:no eating for 2 hours prior and 1 hour after dose
Drug: SAR245409
Pharmaceutical form:capsule Route of administration: oral

Detailed Description:
There is a 21 day screening period followed by 28 day cycles. Patients will continue to receive SAR245409 as long as there is clinical benefit or until a study withdrawal criterion is met. The last posttreatment visit will be 30 days after the last dose or until IMP-related toxicities have resolved or are deemed irreversible, whichever is later.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion criteria:

  • Tissue from an archived or fresh tumor sample
  • A peripheral blood buffy coat sample is required for CLL/SLL.
  • Patient has mantle cell lymphoma (MCL), follicular lymphoma (FL), or chronic lymphocytic leukemia (CLL)/SLL or diffuse large B cell lymphoma
  • Patient > or = 18 years old
  • Eastern Cooperative Oncology Group (ECOG) performance status < or = 2. Patients with DLBCL will have ECOG < or = 1
  • Adequate white blood cells and hemoglobin
  • Good kidney and liver function
  • Fasting glucose < 160 mg/dL
  • No other malignancy
  • Use of adequate birth control

Exclusion criteria:

  • Treatment with cytotoxic chemotherapy, biologic agents, investigational therapies within 4 weeks, or nitrosoureas or mitomycin C within 6 weeks of study enrollment
  • Treatment with a small-molecule kinase inhibitor within 2 weeks, or 5 half lives of the drug or its active metabolites (whichever is longer) of study enrollment
  • Prior treatment with a PI3K, mTOR, or Akt inhibitor. Prior treatment of MCL with temsirolimus is permitted in patients enrolled from countries where it is licensed for this indication.
  • Radiation therapy within 2 weeks of enrollment
  • Autologous stem cell transplantation within 16 weeks of enrollment
  • Prior allogeneic transplantation except for patients with R/R DLBCL who meet inclusion criteria
  • Central nervous system (CNS) or leptomeningeal involvement. Patients with DLBCL may have active CNS or leptomeningeal involvement.
  • Positive Hepatitis B surface antigen (HBsAg) or Hepatitis C antibody (anti-HCV) serology
  • Primary CNS lymphoma
  • Primary mediastinal B-lymphoma

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01403636

  Hide Study Locations
United States, California
Investigational Site Number 840012
Los Angeles, California, United States, 90033
United States, Florida
Investigational Site Number 840104
Fort Meyers, Florida, United States, 33919
United States, Georgia
Investigational Site Number 840006
Augusta, Georgia, United States, 30912
United States, Illinois
Investigational Site Number 840011
Maywood, Illinois, United States, 60153
United States, Kansas
Investigational Site Number 840010
Kansas City, Kansas, United States, 66160-7321
United States, Kentucky
Investigational Site Number 840013
Lexington, Kentucky, United States, 40536
Investigational Site Number 840007
Paducah, Kentucky, United States, 42002
United States, Massachusetts
Investigational Site Number 840004
Boston, Massachusetts, United States, 02115
United States, Missouri
Investigational Site Number 840015
St Louis, Missouri, United States, 63110
United States, Ohio
Investigational Site Number 840014
Canton, Ohio, United States, 44718
United States, Pennsylvania
Investigational Site Number 840001
Philadelphia, Pennsylvania, United States, 19111
United States, West Virginia
Investigational Site Number 840002
Morgantown, West Virginia, United States, 26506
Investigational Site Number 036002
Clayton, Australia, 3168
Investigational Site Number 036001
Hobart, Australia, 7001
Investigational Site Number 036005
Kingswood, Australia, 2747
Investigational Site Number 036003
Perth, Australia, 6000
Investigational Site Number 056003
Bruxelles, Belgium, 1000
Investigational Site Number 056002
Gent, Belgium, 9000
Investigational Site Number 056001
Leuven, Belgium, 3000
Investigational Site Number 250002
Montpellier, France, 34295
Investigational Site Number 250001
Pierre Benite Cedex, France, 69495
Investigational Site Number 250004
Rennes, France, 35033
Investigational Site Number 250005
Rouen Cedex, France, 76038
Investigational Site Number 250003
Villejuif Cedex, France, 94805
Investigational Site Number 276003
Frankfurt Am Main, Germany, 60590
Investigational Site Number 276002
Jena, Germany, 07747
Investigational Site Number 276001
Ulm, Germany, 89081
Investigational Site Number 528001
Amsterdam, Netherlands, 1105 AZ
Investigational Site Number 528003
Groningen, Netherlands, 9713 GZ
Investigational Site Number 528002
Rotterdam, Netherlands, 3075 EA
Sponsors and Collaborators
Study Director: Clinical Sciences & Operations Sanofi
  More Information

Responsible Party: Sanofi Identifier: NCT01403636     History of Changes
Other Study ID Numbers: ARD12130
2011-001616-57 ( EudraCT Number )
U1111-1118-6417 ( Other Identifier: UTN )
Study First Received: July 26, 2011
Last Updated: February 17, 2016

Additional relevant MeSH terms:
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases processed this record on May 23, 2017